[Webmaster's clarification: for citations 1-10 see Legal Citations on arthritis]

11. Abrams, Donald I., et al [2003]. Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection: A Randomized, Placebo-Controlled Clinical Trial. Ann Intern Med. 2003 Aug 19;139(4):258-66.

12. Russo EB. Role of cannabis and cannabinoids in pain management. In: Weiner RS, editor. Pain management: A practical guide for clinicians. 6th ed. Boca Raton, FL: CRC Press; 2002. p. 357-375.

13. 2. Marcandier M. Treatise on hemp. London: T. Becket and P.A. de Hondt; 1764.

14. E. Formukong et al., "Analgesic and Antiinflammatory Activity of Constituents of Cannabis Sativa L.," Inflammation 12 (1988): 361.

15. M.L. Barret et al, "Isolation from Cannabis sativa L. of Cannflavon - a novel inhibitor of prostaglandin production," Biochem. Pharmacol. 34: 2019 (1985);

16. S.H. Burstein et al, "Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid," J Pharmacol. Exp. Therap. 251: 531-5 (1989)

17. R.D. Sofia, "Antiedemic and analgesic properties of delta-9-THC compared with three other drugs," Eur. J. Pharamacol. 41: 705-9 (1989).

18. Zurier RB, et al. Dimethylheptyl-THC-11 Oic Acid: A Nonpsychoactive Antiinflammatory Agent with a Cannabinoid Template Structure. ARTHRITIS AND RHEUMATISM January 1998; volume 41, number 1, pages 163-170.

19. Costa B, et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol. 2004 Mar;369(3):294-9. Epub 2004 Feb 12.

20. Malfait AM, et al. "The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis," Proc Natl Acad Sci U S A. 2000 Aug 15 97(17):9561-6.

21. James JS. Marijuana, inflammation, and CT-3 (DMH-11C): cannabis leads to new class of antiinflammatory drugs. AIDS Treat News. 1998 Jan 23;(No 287):1, 5.

22. Straus SE, "Immunoactive cannabinoids: Therapeutic prospects for marijuana constituents," Proc Natl Acad Sci U S A. 2000 Aug 15 97(17):9563.

23. Shohami, E. Nature. 2001 Oct 4;413(6855):527-31.

24. Burstein SH, "Ajulemic acid (CT3): a potent analog of the acid metabolites of THC," Curr Pharm Des. 2000 Sep 6(13):1339-45.

25. Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: A novel cannabinoid produces analgesia without a "high". Life Sci. 2004 Aug 6;75(12):1513-22.

26. Devane WA, Hanus L, Breur A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.

27. Barg J, Fride E, Hanus L, et al. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur J Pharmacol. 1995;287:145-152.

28. Klein TW, Newton C and Friedman H. Cannabinoid receptors and immunity. Immunol Today. 1998; 797:225- 233.

29. Daaka Y, Friedman H and Klein TW. Cannabinoid receptor proteins are increased in jurkat, human T-cell line after mitogen activation. J Pharmacol Exp Ther. 1996;276:776-783.

30. Kaminski, NE; Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Biochem Pharmacol 1996; 52(8):1133-40,

31. Di Marzo V. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochimica et Biophysica Acta. 1998;1392(2-3):153-75.

32. Smith PB, Compton DR, Welch SP, et al. The pharmacological activity of anandamide, a putative endogenous cannabinoid in mice. J Pharmacol Exp Ther. 1994;270:219-227.

33. Burstein SH. Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr Pharm Des. 2000 Sep;6(13):1339-45.

34. Zurier RB, Rossetti RG, Burstein SH, Bidinger B. Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem Pharmacol. 2003 Feb 15;65(4):649-55.

All rights reserved. Copyright pending 2008.